Bharat Immunologicals & Biologicals Corporation Ltd
- Market cap
- ₹ 40 Cr.
- P/E
- 119x
- P/B
- 0.45x
- 52-week range
- 7.11 – 22.61
- ROE
- −18%
- ROCE
- −9%
- Dividend yield
- 0%
- Debt / equity
- 0.8
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE
About
Bharat Immunologicals and Biologicals Corporation Limited is an India-based biotechnology company. The Company is primarily engaged in the manufacture of oral polio vaccine, zinc tablet, and diarrhea management kit. It operates under various segment, namely oral polio vaccine, zinc tablets, BIB VIT, and BIBSANIT. It is also focused on manufacturing Ready to Use Therapeutic Food (RUTF), which is used for the treatment of malnourishment among various acute malnourished children. The Company is switched over to bivalent oral polio vaccine (bOPV) from trivalent oral polio vaccine (tOPV). It is also diversified into plasma-derived medicines and Oral Cholera vaccines. The Company's manufacturing unit is located at Village Chola, Bulandshahr, Uttar Pradesh, India.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Bharat Immunologicals & Biologicals Corporation Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)119 against a typical 34.3: pricier than most peers (1st = cheapest).197th of 220
- Sales growth−100% against a typical +15.6% from a year earlier.192nd of 197
- Share price, 3 months−43.2% against a typical −0.5%.198th of 200
- Size₹ 40.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).168th of 199
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25 | 16 | 14 | 25 | 17 | 22 | 10 | 26 | 0 | 8 | 0 | 0 |
| Expenses | 27 | 32 | 13 | 28 | 16 | 26 | 15 | 29 | 5 | 12 | 4 | 5 |
| Operating Profit | −2 | −16 | 1 | −3 | 1 | −4 | −5 | −3 | −5 | −4 | −4 | −5 |
| OPM % | −9% | −101.9% | 7.3% | −14.1% | 5.9% | −16.7% | −46.1% | −9.4% | — | −52.6% | — | — |
| Other Income | 1 | 9 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −2 | −8 | 0 | −5 | −0 | −5 | −6 | −4 | −6 | −6 | −6 | −7 |
| Tax % | −21.8% | −19.5% | −2,642.9% | 105.3% | −25% | −11% | −20.8% | −22.2% | −26.1% | −31.7% | −23.2% | −26.1% |
| Net Profit | −2 | −7 | 2 | −9 | −0 | −4 | −5 | −3 | −5 | −4 | −5 | −5 |
| EPS in Rs | −0.44 | −1.51 | 0.45 | −2.17 | −0.08 | −0.99 | −1.16 | −0.71 | −1.08 | −0.9 | −1.06 | −1.14 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- −13%
- 5 Years
- 5%
- 3 Years
- −13%
- TTM
- −90%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- −31%
- TTM
- −42%
- 10 Years
- −5%
- 5 Years
- −28%
- 3 Years
- −25%
- TTM
- —
- 10 Years
- −12%
- 5 Years
- −24%
- 3 Years
- −23%
- TTM
- —
Peers
Listed companies in the same business.
| Bharat Immunologicals & Biologicals Corporation Ltd | ₹ 8.78 | ₹ 40 Cr. | 119x | 0.5x | −18% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Sanjay Kumar Mishra
- Managing Director, Executive Director
- Sandip Kumar Lal
- Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.